PL363967A1 - Sposób i postać dawkowa do leczenia nowotworów drogą podawania tegafuru, uracylu, kwasu folinowego,paklitakselu i karboplatyny - Google Patents

Sposób i postać dawkowa do leczenia nowotworów drogą podawania tegafuru, uracylu, kwasu folinowego,paklitakselu i karboplatyny

Info

Publication number: PL363967A1
Authority: PL; Poland
Prior art keywords: tegafur; carboplatin; paclitaxel; uracil; administration
Prior art date: 2001-03-06

Application number

PL02363967A

Other languages

English (en)

Inventor

Jafferhusen A. Ajani

Steven E. Benner

Terry S. Dugan

Original Assignee

Bristol-Myers Squibb Company

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-03-06

Filing date

2002-03-04

Publication date

2004-11-29

2002-03-04 Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company

2004-11-29 Publication of PL363967A1 publication Critical patent/PL363967A1/pl

Links

ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 title 2
VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 title 1
MPJKWIXIYCLVCU-UHFFFAOYSA-N Folinic acid Natural products NC1=NC2=C(N(C=O)C(CNc3ccc(cc3)C(=O)NC(CCC(=O)O)CC(=O)O)CN2)C(=O)N1 MPJKWIXIYCLVCU-UHFFFAOYSA-N 0.000 title 1
206010028980 Neoplasm Diseases 0.000 title 1
229930012538 Paclitaxel Natural products 0.000 title 1
190000008236 carboplatin Chemical compound 0.000 title 1
229960004562 carboplatin Drugs 0.000 title 1
239000002552 dosage form Substances 0.000 title 1
VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 title 1
235000008191 folinic acid Nutrition 0.000 title 1
239000011672 folinic acid Substances 0.000 title 1
229960001691 leucovorin Drugs 0.000 title 1
229960001592 paclitaxel Drugs 0.000 title 1
RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 title 1
WFWLQNSHRPWKFK-ZCFIWIBFSA-N tegafur Chemical compound O=C1NC(=O)C(F)=CN1[C@@H]1OCCC1 WFWLQNSHRPWKFK-ZCFIWIBFSA-N 0.000 title 1
229960001674 tegafur Drugs 0.000 title 1
229940035893 uracil Drugs 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Oncology (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Epoxy Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Plural Heterocyclic Compounds (AREA)

PL02363967A 2001-03-06 2002-03-04 Sposób i postać dawkowa do leczenia nowotworów drogą podawania tegafuru, uracylu, kwasu folinowego,paklitakselu i karboplatyny PL363967A1 (pl)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US27357701P	2001-03-06	2001-03-06
PCT/US2002/006262 WO2002076459A1 (en)	2001-03-06	2002-03-04	Method and dosage form for treating tumors by the administration of tegafur, uracil, folinic acid, paclitaxel and carboplatin

Publications (1)

Publication Number	Publication Date
PL363967A1 true PL363967A1 (pl)	2004-11-29

Family

ID=23044526

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL02363967A PL363967A1 (pl)	2001-03-06	2002-03-04	Sposób i postać dawkowa do leczenia nowotworów drogą podawania tegafuru, uracylu, kwasu folinowego,paklitakselu i karboplatyny

Country Status (20)

Country	Link
US (1)	US6770653B2 (pl)
EP (1)	EP1368034A1 (pl)
JP (1)	JP2005506294A (pl)
KR (1)	KR20030081496A (pl)
BR (1)	BR0207443A (pl)
CA (1)	CA2439676A1 (pl)
CZ (1)	CZ20032266A3 (pl)
EE (1)	EE200300429A (pl)
HR (1)	HRP20030801A2 (pl)
HU (1)	HUP0303466A3 (pl)
IL (1)	IL157357A0 (pl)
IS (1)	IS6925A (pl)
MX (1)	MXPA03007989A (pl)
NO (1)	NO20033910L (pl)
PL (1)	PL363967A1 (pl)
RU (1)	RU2284184C2 (pl)
SK (1)	SK10602003A3 (pl)
WO (1)	WO2002076459A1 (pl)
YU (1)	YU69903A (pl)
ZA (1)	ZA200306541B (pl)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2002036135A2 (en) *	2000-11-06	2002-05-10	Pharma Mar, S.A.	Compositions for antitumour treatment containing ecteinascidin 743
US9611227B2 (en)	2003-03-14	2017-04-04	Taiho Pharmaceutical Co., Ltd.	Antitumor effect potentiator and antitumor agent
WO2004087105A1 (en) *	2003-04-02	2004-10-14	Celator Pharmaceuticals, Inc.	Combination formulations of platinum agents and fluoropyrimidines
GB0312407D0 (en) *	2003-05-29	2003-07-02	Pharma Mar Sau	Treatment
JP2007511509A (ja) *	2003-11-14	2007-05-10	ファルマ・マール・ソシエダード・アノニマ	Ｅｔ−７４３およびパクリタキセルの使用を含むガンの併用療法
GB0326486D0 (en) *	2003-11-14	2003-12-17	Pharma Mar Sau	Combination treatment
KR20050099311A (ko) *	2004-04-09	2005-10-13	에이엔에이치 케어연구소(주)	주사제용 항암제 조성물
RS50822B (sr) *	2004-10-26	2010-08-31	Pharma Mar S.A., Sociedad Unipersonal	Pegilovani lipozomalni doksorubicin u kombinaciji sa ekteinescidinom 743
KR101188691B1 (ko)	2004-10-29	2012-10-09	파르마 마르 에스.에이.	엑티나시딘 및 디사카라이드를 포함하는 제제
CN103169729A (zh)	2005-02-18	2013-06-26	阿布拉科斯生物科学有限公司	治疗剂的组合和给予方式以及联合治疗
US8735394B2 (en)	2005-02-18	2014-05-27	Abraxis Bioscience, Llc	Combinations and modes of administration of therapeutic agents and combination therapy
GB0522082D0 (en) *	2005-10-31	2005-12-07	Pharma Mar Sa	Formulations
AU2008202078B2 (en) *	2007-10-10	2012-05-31	Wellkey Holdings Limited	Stability of secondary metabolite mass production through synchronized plant cell cultures
WO2009050303A1 (en) *	2007-10-19	2009-04-23	Pharma Mar, S.A.	Prognostic molecular markers for et-743 treatment
KR20130028727A (ko)	2010-03-29	2013-03-19	아브락시스 바이오사이언스, 엘엘씨	치료제의 약물 전달 및 유효성 향상 방법
US9393318B2 (en)	2010-03-29	2016-07-19	Abraxis Bioscience, Llc	Methods of treating cancer
KR20130088116A (ko)	2010-06-04	2013-08-07	아브락시스 바이오사이언스, 엘엘씨	췌장암의 치료 방법
CN107530309A (zh) *	2015-04-22	2018-01-02	新纳特产品公司	共晶组合物及其药物用途
RU2752172C2 (ru)	2016-08-31	2021-07-23	Фуджифилм Корпорэйшн	Противоопухолевый агент, усилитель противоопухолевого действия и противоопухолевый набор
RU2646450C1 (ru) *	2017-05-11	2018-03-05	Владимир Михайлович Курусин	Способ лечения предраковых и ранних стадий раковых заболеваний желудка
MX2018002611A (es)	2018-01-29	2019-07-30	Fujifilm Corp	Agente antitumoral para cancer del tracto biliar y metodo para tratar cancer del tracto biliar.

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5A (en) *		1836-08-10	Thomas Blanchard	Machine for mortising solid wooden shells of ships' tackle-blocks
US4328229A (en)	1978-03-29	1982-05-04	Taiho Pharmaceutical Company Limited	Anti-cancer composition for delivering 5-fluorouracil to cancer tissues
US5534513A (en)	1991-09-05	1996-07-09	Taiho Pharmaceutical Company, Ltd.	Antitumor potentiator and antitumor composition
FR2697752B1 (fr) *	1992-11-10	1995-04-14	Rhone Poulenc Rorer Sa	Compositions antitumorales contenant des dérivés du taxane.
US5919816A (en) *	1994-11-14	1999-07-06	Bionumerik Pharmaceuticals, Inc.	Formulations and methods of reducing toxicity of antineoplastic agents
RU2194541C1 (ru) *	2001-07-13	2002-12-20	Научно-исследовательский институт онкологии Томского научного центра СО РАН	Способ комбинированного лечения больных местнораспространенным раком желудка

2002
- 2002-03-04 US US10/090,354 patent/US6770653B2/en not_active Expired - Fee Related
- 2002-03-04 JP JP2002574974A patent/JP2005506294A/ja active Pending
- 2002-03-04 EP EP02713715A patent/EP1368034A1/en not_active Withdrawn
- 2002-03-04 RU RU2003129527/14A patent/RU2284184C2/ru not_active IP Right Cessation
- 2002-03-04 MX MXPA03007989A patent/MXPA03007989A/es unknown
- 2002-03-04 HU HU0303466A patent/HUP0303466A3/hu unknown
- 2002-03-04 WO PCT/US2002/006262 patent/WO2002076459A1/en not_active Ceased
- 2002-03-04 HR HR20030801A patent/HRP20030801A2/hr not_active Application Discontinuation
- 2002-03-04 SK SK10602003A patent/SK10602003A3/sk not_active Application Discontinuation
- 2002-03-04 CZ CZ20032266A patent/CZ20032266A3/cs unknown
- 2002-03-04 PL PL02363967A patent/PL363967A1/pl not_active Application Discontinuation
- 2002-03-04 CA CA002439676A patent/CA2439676A1/en not_active Abandoned
- 2002-03-04 KR KR10-2003-7011636A patent/KR20030081496A/ko not_active Withdrawn
- 2002-03-04 BR BR0207443-5A patent/BR0207443A/pt not_active IP Right Cessation
- 2002-03-04 EE EEP200300429A patent/EE200300429A/xx unknown
- 2002-03-04 IL IL15735702A patent/IL157357A0/xx unknown
- 2002-03-04 YU YU69903A patent/YU69903A/sh unknown
2003
- 2003-08-21 ZA ZA200306541A patent/ZA200306541B/xx unknown
- 2003-08-22 IS IS6925A patent/IS6925A/is unknown
- 2003-09-04 NO NO20033910A patent/NO20033910L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
US20020173482A1 (en)	2002-11-21
MXPA03007989A (es)	2003-12-04
EE200300429A (et)	2003-12-15
WO2002076459A1 (en)	2002-10-03
YU69903A (sh)	2006-08-17
KR20030081496A (ko)	2003-10-17
RU2284184C2 (ru)	2006-09-27
EP1368034A1 (en)	2003-12-10
JP2005506294A (ja)	2005-03-03
CZ20032266A3 (cs)	2004-02-18
US6770653B2 (en)	2004-08-03
CA2439676A1 (en)	2002-10-03
HRP20030801A2 (en)	2004-08-31
IS6925A (is)	2003-08-22
NO20033910L (no)	2003-10-23
NO20033910D0 (no)	2003-09-04
HUP0303466A3 (en)	2005-02-28
HUP0303466A2 (hu)	2004-01-28
IL157357A0 (en)	2004-02-19
BR0207443A (pt)	2004-04-06
ZA200306541B (en)	2004-11-22
RU2003129527A (ru)	2005-03-10
SK10602003A3 (en)	2004-10-05

Legal Events

Date	Code	Title	Description
2010-05-31	REFS	Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)

Publication	Publication Date	Title
ZA200306541B (en)	2004-11-22	Method and dosage form for treating tumors by the administration of tegafur, uracil, folinic acid, paclitaxel and carboplatin.
IL164135A (en)	2011-07-31	4-anilino quinazoline derivatives as antiproliferative agents, process for their preparation, pharmaceutical compositions containing such derivatives and use thereof for the preparation of medicaments for the treatment of cancer
IL162348A (en)	2010-11-30	Oxaliplatin formulations, method for stabilizing same and use thereof for preparing medicaments for treating cancer
HUP0301046A3 (en)	2008-12-29	Quinazoline derivatives for the treatment of tumours, process for their preparation and pharmaceutical compositions containing them
WO2003080582A3 (de)	2004-12-09	Fredericamycin-derivate
WO1999054326A8 (de)	1999-12-29	Dihydropyrimidine
HUP0402588A3 (en)	2009-09-28	Quinazoline derivatives, pharmaceutical compositions containing them, process for producing them and their use
WO2002062763A3 (en)	2002-10-10	Inhibition of raf kinase using quinolyl isoquinolyl or pyridyl ureas
HUP0401346A3 (en)	2009-03-02	Hiv inhibiting pyrimidines derivatives, process for their preparation and pharmaceutical compositions containing them
WO2002085857A3 (en)	2003-01-16	Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
WO2005110994A3 (en)	2006-02-02	Substituted pyrazolyl urea derivatives useful in the treatment of cancer
IL219397A0 (en)	2012-06-28	Compounds for the treatment of metabolic disorders, methods of preparing same, and pharmaceutical compositions containing same
HUP0204399A3 (en)	2004-11-29	Pteridine compounds for the treatment of psoriasis, process for their preparation, pharmaceutical compositions containing them and their use
WO2003084539A3 (en)	2004-09-02	New pharmaceutical compositions based on anticholinergics and p38 kinase inhibitors
MXPA03006538A (es)	2003-09-22	Nuevos derivados de urea, su procedimiento de preparacion, su aplicacion como medicamentos, composiciones farmaceuticas y nueva utilizacion.
PL378369A1 (pl)	2006-04-03	Sposób leczenia mdłości, wymiotów, nudności lub ich dowolnej kombinacji
WO2004007676A3 (en)	2004-04-08	Combination therapy for the treatment of neoplasms
MXPA03001484A (es)	2003-06-06	Quinazolinas, medicamentos que contienen estos compuestos, y son efectivos como inhbidores de tirosina quinasa, su utilizacion y metodos para su produccion.
AU2001240001A1 (en)	2001-09-17	Oral dosage form for administration of the combination of tegafur, uracil, folinic acid, and oxaliplatin and method of using the same
MXPA05009781A (es)	2005-10-26	Potenciador de efecto antitumoral y agente antitumoral.
PL373247A1 (pl)	2005-08-22	Sposób leczenia nowotworów drogą podawania tegafuru, uracylu, kwasu folinowego i cyklofosfoamidu
HUP0202832A3 (en)	2003-03-28	New pyrimidine-2,4,6-trione derivatives, processes for their production and pharmaceutical agents containing these compounds
PL357179A1 (pl)	2004-07-26	Stosowanie kwasu 2-metylotiazolidyno-2,4-dikarboksylowego (2-MTDC) i/lub jego fizjologicznie dopuszczalnych soli jako środka przeciwnowotworowego
HK1060518A (en)	2004-08-13	Method and dosage form for treating tumors by the administration of tegafur, uracil, folinic acid, paclitaxel and carboplatin
MXPA04000272A (es)	2004-05-04	Derivados de 4-aminociclohexanol sustituidos.